Sun Pharmaceutical Industries is currently trading at Rs. 806.75, up by 2.00 points or 0.25% from its previous closing of Rs. 804.75 on the BSE.
The scrip opened at Rs. 810.00 and has touched a high and low of Rs. 811.00 and Rs. 802.10 respectively. So far 27605 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1010.10 on 25-May-2015 and a 52 week low of Rs. 706.40 on 24-Nov-2015.
Last one week high and low of the scrip stood at Rs. 827.40 and Rs. 780.55 respectively. The current market cap of the company is Rs. 195139.61 crore.
The promoters holding in the company stood at 54.97% while Institutions and Non-Institutions held 35.37% and 9.65% respectively.
Sun Pharmaceutical Industries has launched an innovative mobile app to connect doctors with asthma patients. The company has developed the app to facilitate doctors to track treatment progress of their patients and increase compliance to medication for better management of asthma.
It is estimated that nearly 50 per cent to 70 per cent patients in India do not adhere to asthma treatment regimen recommended by a doctor. Sun Pharma’s RespiTrack app aims to address these and other reasons leading to non-adherence thereby improving compliance to Asthma treatment through recurring medication reminders, pre-programmed alerts, over-the-air review by the doctor etc.
Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. Its global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1904.65 |
| Dr. Reddys Labs. | 1374.55 |
| Cipla | 1458.45 |
| Zydus Lifesciences | 1141.00 |
| Lupin | 2476.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: